APA (7th ed.) Citation

K, F., ZF, N., I, I., H, E., C, B., B, T., & J, D. (2023). Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University. Pathology oncology research : POR, 29, 1611378. https://doi.org/10.3389/pore.2023.1611378

Chicago Style (17th ed.) Citation

K, Ferenczi, Nagy ZF, Istenes I, Eid H, Bödör C, Timár B, and Demeter J. "Long Term Follow-up of Refractory/relapsed Hairy Cell Leukaemia Patients Treated with Low-dose Vemurafenib Between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University." Pathology Oncology Research : POR 29 (2023): 1611378. https://doi.org/10.3389/pore.2023.1611378.

MLA (9th ed.) Citation

K, Ferenczi, et al. "Long Term Follow-up of Refractory/relapsed Hairy Cell Leukaemia Patients Treated with Low-dose Vemurafenib Between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University." Pathology Oncology Research : POR, vol. 29, 2023, p. 1611378, https://doi.org/10.3389/pore.2023.1611378.